Orchard Therapeutics

Orchard Therapeutics is a British gene therapy company founded in 2015. Its scientific roots reach back to early research and clinical development of ex vivo autologous hematopoietic stem cell (HSC) gene therapy. Orchard identifies Bobby Gaspar, M.D., Ph.D., and Donald Kohn, M.D., as scientific founders involved in early clinical studies in this field. The company describes its work as carrying forward that history of research to develop treatments for people and families affected by genetic and other severe diseases. Orchard’s core approach is to modify a patient’s own blood stem cells outside the body and return them to the patient. The intended aim is to correct an underlying disease cause through a single treatment. The company has described a portfolio spanning preclinical, clinical and commercial-stage HSC gene therapies, with an emphasis on conditions where disease burden is high and existing treatment options are limited or absent. Its stated areas of work include severe genetic diseases and neurometabolic disorders. Orchard also highlights patient and family experiences and works with research partners on clinical trials of investigational therapies. A significant commercial offering associated with Orchard is atidarsagene autotemcel, sold under the names Libmeldy in the European Union and Lenmeldy in the United States. The supplied evidence identifies it as authorized in both markets for children with early-onset metachromatic leukodystrophy (MLD). Orchard’s family resources include educational material about gene therapy, MLD and MPS, as well as information about clinical trials and access policy. Kyowa Kirin announced its acquisition of Orchard in October 2023, and the acquisition was completed in January 2024. Orchard therefore operates as part of the Kyowa Kirin group. Its public-facing mission continues to emphasize the potential of HSC gene therapy and the needs of people living with severe genetic diseases.

Orchard Therapeutics was founded in 2015, but the company describes its scientific roots as reaching further back, into the early research and clinical development of ex vivo autologous HSC gene therapy. Its account of that history situates Orchard within a broader scientific field rather than presenting the underlying technology as originating with the company. Orchard identifies Bobby Gaspar and Donald Kohn as scientific founders who took part in some of the early clinical studies of ex vivo autologous gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company’s historical account traces the field to a 1990 clinical trial at the National Institutes of Health, in which two children with ADA-SCID received regular infusions of gene-corrected versions of their own cells. Results from that trial were published in 1995. Orchard presents these developments as part of the research lineage behind its work. Its stated focus is applying HSC gene therapy to significant medical needs, with the aim of treating the underlying cause of severe genetic diseases. The approach modifies a patient’s own blood stem cells outside the body and returns them, with the intended goal of correcting the cause of disease in a single treatment. Orchard has described its portfolio as spanning preclinical, clinical and commercial-stage HSC gene therapies. Its public materials refer to investigational programs for genetic and other severe diseases, including neurometabolic disorders, and to clinical trials conducted with research partners. The company also presents patient and family stories, educational information and access-policy material as part of its engagement with affected communities. The best-known commercial offering associated with Orchard is atidarsagene autotemcel, marketed as Libmeldy in the European Union and Lenmeldy in the United States for early-onset metachromatic leukodystrophy. In October 2023, Kyowa Kirin announced that it would acquire Orchard Therapeutics. The transaction was completed in January 2024, placing Orchard within the Kyowa Kirin group. These developments mark Orchard’s progression from a specialist gene therapy company to a subsidiary of a larger pharmaceutical group while its public-facing work remains centered on HSC gene therapy and severe genetic diseases.

• An early ex vivo autologous gene therapy clinical trial began at the National Institutes of Health.

• Orchard scientific founders Bobby Gaspar and Donald Kohn were involved in early ADA-SCID gene therapy clinical studies.

• Results from the first clinical trial of ex vivo autologous gene therapy were published.

• Orchard Therapeutics was founded.

• Kyowa Kirin announced its acquisition of Orchard Therapeutics.

• Kyowa Kirin completed the acquisition of Orchard Therapeutics.

A gene therapy company applying its HSC gene therapy platform to severe genetic diseases and areas of significant medical need, including conditions with limited or no existing treatment options.

• Libmeldy (atidarsagene autotemcel)

  A gene therapy identified in the supplied evidence as authorized in the European Union for children with early-onset metachromatic leukodystrophy.

• Lenmeldy (atidarsagene autotemcel)

  The United States name for atidarsagene autotemcel, identified in the supplied evidence as authorized for children with early-onset metachromatic leukodystrophy.

1. 1Homepage - Orchard Therapeuticsorchard-tx.com
2. 2Our Story - Orchard Therapeuticsorchard-tx.com
3. 3Families - Orchard Therapeuticsorchard-tx.com
4. 4Orchard Therapeuticswikidata.org
5. 5Kyōwa Kirinde.wikipedia.org
6. 6Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directorsbiospace.com